{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:30:28Z","timestamp":1793395828280,"version":"4.5.0"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thebreastonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Breast"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.breast.2026.104921","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:45:53Z","timestamp":1789627553000},"page":"104921","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"Fatima","family":"Cardoso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana Mourato","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Schumacher-Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1320-3830","authenticated-orcid":false,"given":"Sandra M.","family":"Swain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shani","family":"Paluch-Shimon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4279-5492","authenticated-orcid":false,"given":"Frederique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2263-5413","authenticated-orcid":false,"given":"Nancy U.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-9286","authenticated-orcid":false,"given":"Prudence A.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1719-7052","authenticated-orcid":false,"given":"Marion","family":"Kuper-Hommel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0643-3790","authenticated-orcid":false,"given":"Anne","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6764-3102","authenticated-orcid":false,"given":"Florentine","family":"Hilbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0318-9120","authenticated-orcid":false,"given":"Angel","family":"Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matti S.","family":"Aapro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Azmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Bajpai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-8658","authenticated-orcid":false,"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran","family":"Boyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4649","authenticated-orcid":false,"given":"Lisa A.","family":"Carey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7189-0763","authenticated-orcid":false,"given":"Mariana","family":"Chavez-MacGregor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7623-1583","authenticated-orcid":false,"given":"Javier","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1720-5673","authenticated-orcid":false,"given":"Amanda","family":"Drury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9612-4224","authenticated-orcid":false,"given":"Nagi S.","family":"El Saghir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elghazaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6666-5599","authenticated-orcid":false,"given":"Alexandru","family":"Eniu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0577-4518","authenticated-orcid":false,"given":"Lesley","family":"Fallowfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1690-1941","authenticated-orcid":false,"given":"Sandra Ximena","family":"Franco Millan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4111-2757","authenticated-orcid":false,"given":"Karen","family":"Gelmon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8377-1633","authenticated-orcid":false,"given":"Jenny","family":"Gilchrist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Gligorov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2772-3140","authenticated-orcid":false,"given":"William J.","family":"Gradishar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9744-7372","authenticated-orcid":false,"given":"Nadia","family":"Harbeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orit","family":"Kaidar-Person","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjit","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1662-3523","authenticated-orcid":false,"given":"Belinda","family":"Kiely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Bae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Kutika","family":"Nyagabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkmar","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Neciosup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Ohno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9184-7199","authenticated-orcid":false,"given":"Barbara","family":"Pistilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7789-0170","authenticated-orcid":false,"given":"Tanja","family":"Spanic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-5987","authenticated-orcid":false,"given":"Janice","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Vuylsteke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.breast.2026.104921_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104612","article-title":"Improving equitable access to comprehensive care for people with advanced breast cancer: a global expert review and call-to-action for 2025\u20132035 (Goal 9)","volume":"84","author":"Eniu","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104921_bib2","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.breast.2012.03.003","article-title":"1st International consensus guidelines for advanced breast cancer (ABC 1)","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104921_bib3","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/annonc\/mdu385","article-title":"ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)","volume":"25","author":"Cardoso","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdw544","article-title":"3rd ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 3)","volume":"28","author":"Cardoso","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib5","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO\u2013ESMO international consensus guidelines for advanced breast cancer (ABC 4)","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib6","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib7","unstructured":"https:\/\/www.abcglobalalliance.org\/n.d."},{"key":"10.1016\/j.breast.2026.104921_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104601","article-title":"Knowledge in motion: a decade reviewed, a future defined \u2013 the ABC global alliance 2015\u20132025 decade report and 2025\u20132035 global charter","volume":"84","author":"Cardoso","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104921_bib9","series-title":"ABC global charter report (2015\u20132025)","year":"2025"},{"key":"10.1016\/j.breast.2026.104921_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th international consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104921_bib11","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.breast.2026.104921_bib12","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.1019","article-title":"Clinico-molecular characteristics associated with outcomes in breast cancer patients treated with CDK4\/6 inhibitors: results from the AURORA molecular screening initiative","volume":"41","author":"Agostinetto","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101931","volume":"59","author":"Lambertini","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.breast.2026.104921_bib14","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.1011","article-title":"Comprehensive clinical characteristics and ctDNA mutational profile analysis of endocrine resistance\/sensitivity to adjuvant ET therapy in luminal breast cancer from the GEICAM\/2014-03_RegistEM registry","volume":"42","author":"Guerrero","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105309","article-title":"Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive\/HER2-negative advanced breast cancer in the PARSIFAL trial","volume":"10","author":"Llombart-Cussac","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104921_bib16","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1038\/s41591-024-03143-y","article-title":"Supervised, structured and individualized exercise in metastatic breast cancer: a randomized controlled trial","volume":"30","author":"Hiensch","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104921_bib17","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1002\/ijc.35429","article-title":"Impact of exercise on sexual health, body image, and therapy\u2010related symptoms in women with metastatic breast cancer: the randomized controlled <scp>PREFERABLE<\/scp> \u2010 <scp>EFFECT<\/scp> trial","volume":"157","author":"Schmidt","year":"2025","journal-title":"Int J Cancer"},{"key":"10.1016\/j.breast.2026.104921_bib18","article-title":"Effectiveness of physical exercise on the cardiovascular system in breast cancer patients: a systematic review and meta-analysis of randomized controlled trials","volume":"44","author":"Wang","year":"2021","journal-title":"Compl Ther Clin Pract"},{"key":"10.1016\/j.breast.2026.104921_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40959-024-00235-z","article-title":"Effectiveness of exercise modalities on breast cancer patient outcomes: a systematic review and meta-analysis","volume":"10","author":"Yamani","year":"2024","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.breast.2026.104921_bib20","first-page":"328","article-title":"Prevalence and clinical implications of sarcopenia in breast cancer: a systematic review and meta-analysis","volume":"32","author":"Jang","year":"2024","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.breast.2026.104921_bib21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s10549-016-3900-2","article-title":"Impact of resistance and aerobic exercise on sarcopenia and dynapenia in breast cancer patients receiving adjuvant chemotherapy: a multicenter randomized controlled trial","volume":"158","author":"Adams","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104921_bib22","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1249\/MSS.0000000000002116","article-title":"Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable","volume":"51","author":"Campbell","year":"2019","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.breast.2026.104921_bib23","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1200\/JCO-24-01441","article-title":"Supervised exercise for patients with metastatic breast cancer: a cost-utility analysis alongside the PREFERABLE-EFFECT randomized controlled trial","volume":"43","author":"Schouten","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib24","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s11764-021-01002-0","article-title":"Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review","volume":"15","author":"Gubler-Gut","year":"2021","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.breast.2026.104921_bib25","doi-asserted-by":"crossref","first-page":"e697","DOI":"10.1200\/OP.21.00454","article-title":"Exercise recommendation for people with bone metastases: expert consensus for health care providers and exercise professionals","volume":"18","author":"Campbell","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.breast.2026.104921_bib26","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08035-2","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.breast.2026.104921_bib27","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2\u2212, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib28","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib29","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.23.01940","volume":"42","author":"Mayer","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib30","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.22.02392","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib31","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1200\/JCO-24-01865","article-title":"Second-line endocrine therapy with or without palbociclib rechallenge in patients with hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: PALMIRA trial","volume":"43","author":"Llombart-Cussac","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib32","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1200\/JCO-24-02086","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib33","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.22.00338","article-title":"Elacestrant (oral selective estrogen receptor degrader) versus standard endocrine therapy for estrogen receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative advanced breast cancer: results from the randomized phase III EMERALD trial","volume":"40","author":"Bidard","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa2410858","article-title":"Imlunestrant with or without Abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib35","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1 -Mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib36","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-RF7-02","article-title":"Abstract RF7-02: alpelisib plus fulvestrant for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after a CDK4\/6 inhibitor (EPIK-B5): phase III, randomized, double-blind, placebo-controlled, multicenter study","volume":"32","author":"De Laurentiis","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104921_bib37","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJMoa2404625","article-title":"Inavolisib-based therapy in PIK3CA -Mutated advanced breast cancer","volume":"391","author":"Turner","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib38","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1056\/NEJMoa2501796","article-title":"Overall survival with Inavolisib in PIK3CA -Mutated advanced breast cancer","volume":"393","author":"Jhaveri","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib39","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1200\/JCO-25-02643","article-title":"VIKTORIA-1 trial of gedatolisib plus fulvestrant with or without palbociclib in hormone Receptor\u2013Positive\/HER2\u2212\/PIK3CA wild-type advanced breast cancer","volume":"44","author":"Hurvitz","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib40","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib41","doi-asserted-by":"crossref","first-page":"S1264","DOI":"10.1016\/j.annonc.2023.10.015","article-title":"LBA11 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+\/HER2\u2013) breast cancer (BC): primary results from the randomised phase III TROPION-Breast01 trial","volume":"34","author":"Bardia","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib42","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-GS1-09","article-title":"Abstract GS1-09: sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+\/HER2\u2212 (IHC 0, 1+, 2+\/ISH\u2212) metastatic breast cancer: primary results from ASCENT-07","volume":"32","author":"Jhaveri","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104921_bib43","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib44","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","article-title":"Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study","volume":"21","author":"Swain","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib45","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus Trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib46","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104921_bib47","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab Deruxtecan plus pertuzumab for HER2-Positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa2511218","article-title":"Palbociclib for Hormone-Receptor\u2013Positive, HER2-Positive advanced breast cancer","volume":"394","author":"Metzger","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib49","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1200\/JCO-25-02600","article-title":"HER2CLIMB-05: a phase III study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer","volume":"44","author":"Dieras","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib50","doi-asserted-by":"crossref","DOI":"10.1158\/1557-3265.SABCS25-GS1-01","article-title":"Abstract GS1-01: Her2climb-05: a randomized, double-blind, phase 3 study of tucatinib versus placebo in combination with trastuzumab and pertuzumab as maintenance therapy for her2+ metastatic breast cancer","volume":"32","author":"Hamilton","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104921_bib51","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMoa2508959","article-title":"Sacituzumab Govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib52","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa2202809","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib53","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1056\/NEJMoa2511734","article-title":"Sacituzumab Govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cort\u00e9s","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib54","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.annonc.2026.03.008","article-title":"Datopotamab deruxtecan in patients with untreated, advanced triple-negative breast cancer (TROPION-Breast02): a randomised, open-label, international, phase III trial","volume":"37","author":"Dent","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib55","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib56","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa1802905","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib57","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.annonc.2024.04.005","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO precision medicine working group","volume":"35","author":"Mosele","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib58","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1200\/JCO.24.00248","article-title":"Endocrine and targeted therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast Cancer\u2014Capivasertib-Fulvestrant: ASCO rapid recommendation update","volume":"42","author":"Burstein","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib59","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s10549-024-07376-w","article-title":"Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(\u2212) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice","volume":"207","author":"Bhave","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104921_bib60","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO precision medicine working group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib61","doi-asserted-by":"crossref","first-page":"3423","DOI":"10.1200\/JCO.23.00638","article-title":"Testing for ESR1 mutations to guide therapy for hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013Negative metastatic breast cancer: ASCO guideline rapid recommendation update","volume":"41","author":"Burstein","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2025.100925","article-title":"International expert consensus recommendations for HER2 reporting in breast cancer: focus on HER2-Low and ultralow categories","volume":"39","author":"Rakha","year":"2026","journal-title":"Mod Pathol"},{"key":"10.1016\/j.breast.2026.104921_bib63","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.path.2025.07.004","article-title":"Hormone receptor and HER2 testing in breast cancer","volume":"18","author":"Solarewicz","year":"2025","journal-title":"Surg Pathol Clin"},{"key":"10.1016\/j.breast.2026.104921_bib64","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41523-025-00872-2","article-title":"HER2-low and ultralow expression of invasive breast carcinoma: clinicopathological features and immunohistochemical consistency analysis","volume":"12","author":"Dong","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.breast.2026.104921_bib65","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.annonc.2023.08.003","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib66","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-024-03462-0","article-title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","volume":"31","author":"Okines","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104921_bib67","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.annonc.2025.10.019","article-title":"Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase III trial","volume":"37","author":"Harbeck","year":"2026","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib68","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1056\/NEJMoa2514661","article-title":"Trastuzumab deruxtecan in residual HER2-Positive early breast cancer","volume":"394","author":"Loibl","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib69","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-Positive breast cancer","volume":"380","author":"von Minckwitz","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib70","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1056\/NEJMoa2406070","article-title":"Survival with trastuzumab emtansine in residual HER2-Positive breast cancer","volume":"392","author":"Geyer","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib71","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO clinical practice guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib72","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1093\/neuonc\/noaa285","article-title":"The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis","volume":"23","author":"Kuksis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib73","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/jnci\/djaf048","article-title":"Prevalence by therapy line and incidence of breast cancer brain metastases in 18 075 patients","volume":"117","author":"Sammons","year":"2025","journal-title":"J Natl Cancer Inst: J Natl Cancer Inst"},{"key":"10.1016\/j.breast.2026.104921_bib74","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/annonc\/mdg300","article-title":"Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival","volume":"14","author":"Miller","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib75","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ijrobp.2009.06.030","article-title":"The effect of early detection of occult brain metastases in HER2-Positive breast cancer patients on survival and cause of death","volume":"77","author":"Niwi\u0144ska","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2026.104921_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2025.104558","article-title":"Brain imaging screening in metastatic breast cancer: patients' and physicians' perspectives","volume":"84","author":"Matos","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.breast.2026.104921_bib77","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/neuonc\/noaf018","article-title":"Phase II trial of brain MRI surveillance in stage IV breast cancer","volume":"27","author":"Ahmed","year":"2025","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib78","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS23-PO2-27-09","article-title":"Abstract PO2-27-09: clinical impact of routine MRI screening for brain metastases in patients with HER2 positive or triple negative metastatic breast cancer","volume":"84","author":"Kim","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.breast.2026.104921_bib79","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1158\/1078-0432.CCR-25-3557","article-title":"Proactive brain screening using contrast-enhanced brain CT scans in HER2+ metastatic breast cancer","volume":"32","author":"Griguolo","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.breast.2026.104921_bib80","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamaoncol.2018.0813","article-title":"Implications of screening for brain metastases in patients with breast cancer and non\u2013small cell lung cancer","volume":"4","author":"Cagney","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib81","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ijrobp.2016.03.013","article-title":"Single-fraction versus multifraction (3 \u00d7 9 gy) stereotactic radiosurgery for large (>2 cm) brain metastases: a comparative analysis of local control and risk of radiation-induced brain necrosis","volume":"95","author":"Minniti","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.breast.2026.104921_bib82","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.2011","article-title":"Stereotactic radiation versus hippocampal avoidance whole brain radiation in patients with 5-20 brain metastases: a multicenter, phase 3 randomized trial","volume":"43","author":"Aizer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib83","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jama.2026.0076","article-title":"Treatment for brain metastases with stereotactic radiation vs hippocampal-avoidance whole brain radiation: a randomized clinical trial","volume":"335","author":"Aizer","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2026.104921_bib84","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1001\/jamaoncol.2022.5610","article-title":"Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with brain metastases","volume":"9","author":"Lin","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.breast.2026.104921_bib85","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.breast.2026.104921_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104921_bib87","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1056\/NEJMoa2415566","article-title":"Elinzanetant for vasomotor symptoms from endocrine therapy for breast cancer","volume":"393","author":"Cardoso","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.breast.2026.104921_bib88","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/GME.0000000000002354","article-title":"Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2)","volume":"31","author":"Nappi","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.breast.2026.104921_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2026.107188","article-title":"234P Elinzanetant in breast cancer care: potential drug\u2013drug interaction profile with targeted systemic therapies","volume":"11","author":"Brennan","year":"2026","journal-title":"ESMO Open"},{"key":"10.1016\/j.breast.2026.104921_bib90","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.2016.20939","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer","volume":"317","author":"Nangia","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2026.104921_bib91","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1001\/jama.2016.21038","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.breast.2026.104921_bib92","doi-asserted-by":"crossref","first-page":"e1386","DOI":"10.1093\/oncolo\/oyae116","article-title":"Results of the Dutch scalp cooling registry in 7424 patients: analysis of determinants for scalp cooling efficacy","volume":"29","author":"Brook","year":"2024","journal-title":"Oncologist"},{"key":"10.1016\/j.breast.2026.104921_bib93","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10549-018-4855-2","article-title":"Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling","volume":"171","author":"Mart\u00edn","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.breast.2026.104921_bib94","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","article-title":"Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study","volume":"88","author":"Kang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.breast.2026.104921_bib95","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jaad.2024.11.048","article-title":"Tolerability and effectiveness of low-dose oral minoxidil for alopecia in patients with breast cancer: a retrospective cohort study","volume":"92","author":"Zaminski","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.breast.2026.104921_bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jdrv.2025.03.015","article-title":"Efficacy of bimatoprost in treating chemotherapy-induced milphosis: a comprehensive review of randomized controlled trials","volume":"4","author":"Gaumond","year":"2025","journal-title":"JAAD Rev"},{"key":"10.1016\/j.breast.2026.104921_bib97","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1097\/DSS.0000000000000755","article-title":"Bimatoprost 0.03% for the treatment of eyebrow hypotrichosis","volume":"42","author":"Carruthers","year":"2016","journal-title":"Dermatol Surg"}],"container-title":["The Breast"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960977626002316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:38:34Z","timestamp":1793392714000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960977626002316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":97,"alternative-id":["S0960977626002316"],"URL":"https:\/\/doi.org\/10.1016\/j.breast.2026.104921","relation":{},"ISSN":["0960-9776"],"issn-type":[{"value":"0960-9776","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"8th International consensus guidelines for the management of advanced breast cancer (ABC8 guidelines)","name":"articletitle","label":"Article Title"},{"value":"The Breast","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.breast.2026.104921","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"104921"}}